Cargando…

IGFBP2 expression predicts IDH-mutant glioma patient survival

Mutations of the isocitrate dehydrogenase (IDH) 1 and 2 genes occur in ~80% of lower-grade (WHO grade II and grade III) gliomas. Mutant IDH produces (R)-2-hydroxyglutarate, which induces DNA hypermethylation and presumably drives tumorigenesis. Interestingly, IDH mutations are associated with improv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Lin Eric, Cohen, Adam L., Colman, Howard, Jensen, Randy L., Fults, Daniel W., Couldwell, William T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352106/ https://www.ncbi.nlm.nih.gov/pubmed/27852048 http://dx.doi.org/10.18632/oncotarget.13329

Ejemplares similares

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
por: Liu, Yanwei, et al.
Publicado: (2022)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

NGMA-1. Quantification of IDH mutant alleles predicts outcome in diffuse gliomas
por: Voisin, Mathew, et al.
Publicado: (2021)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
por: Huang, L. Eric
Publicado: (2022)

Mutant IDH1 regulates the tumor-associated immune system in gliomas
por: Amankulor, Nduka M., et al.
Publicado: (2017)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice
por: Richardson, Leland G., et al.
Publicado: (2020)

Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma
por: Murnyak, Balazs, et al.
Publicado: (2021)

The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma
por: Tiburcio, Patricia D.B., et al.
Publicado: (2020)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling
por: Wang, Qiangwei, et al.
Publicado: (2018)

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
por: Wang, Yuxiang, et al.
Publicado: (2020)

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
por: Shi, Diana D., et al.
Publicado: (2022)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas
por: Ferreyra Vega, Sandra, et al.
Publicado: (2023)

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
por: Wollring, Michael M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mj4sfqq4m6q9dudgboe0hf8s5l